Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Research & Development (2023 - 2025)

Historic Research & Development for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $70.6 million.

  • Immunocore Holdings' Research & Development rose 3373.51% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.9 million, marking a year-over-year increase of 2418.57%. This contributed to the annual value of $222.2 million for FY2024, which is 3583.48% up from last year.
  • Immunocore Holdings' Research & Development amounted to $70.6 million in Q3 2025, which was up 3373.51% from $69.0 million recorded in Q2 2025.
  • Immunocore Holdings' Research & Development's 5-year high stood at $171.0 million during Q4 2022, with a 5-year trough of -$27.4 million in Q1 2021.
  • For the 5-year period, Immunocore Holdings' Research & Development averaged around $40.7 million, with its median value being $48.3 million (2023).
  • As far as peak fluctuations go, Immunocore Holdings' Research & Development surged by 73101.82% in 2022, and later crashed by 7335.18% in 2023.
  • Immunocore Holdings' Research & Development (Quarter) stood at -$27.1 million in 2021, then skyrocketed by 731.02% to $171.0 million in 2022, then plummeted by 73.35% to $45.6 million in 2023, then soared by 33.55% to $60.8 million in 2024, then rose by 15.98% to $70.6 million in 2025.
  • Its last three reported values are $70.6 million in Q3 2025, $69.0 million for Q2 2025, and $56.5 million during Q1 2025.